GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » EV-to-EBIT

Alto Neuroscience (Alto Neuroscience) EV-to-EBIT : -26.71 (As of May. 13, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alto Neuroscience's Enterprise Value is $290.10 Mil. Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.86 Mil. Therefore, Alto Neuroscience's EV-to-EBIT for today is -26.71.

The historical rank and industry rank for Alto Neuroscience's EV-to-EBIT or its related term are showing as below:

ANRO' s EV-to-EBIT Range Over the Past 10 Years
Min: -68.14   Med: 0   Max: 0
Current: -26.71

ANRO's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs ANRO: -26.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alto Neuroscience's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil. Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.86 Mil. Alto Neuroscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.


Alto Neuroscience EV-to-EBIT Historical Data

The historical data trend for Alto Neuroscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience EV-to-EBIT Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
EV-to-EBIT - - - - -

Competitive Comparison of Alto Neuroscience's EV-to-EBIT

For the Biotechnology subindustry, Alto Neuroscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alto Neuroscience's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's EV-to-EBIT falls into.



Alto Neuroscience EV-to-EBIT Calculation

Alto Neuroscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=290.103/-10.861
=-26.71

Alto Neuroscience's current Enterprise Value is $290.10 Mil.
Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience  (NYSE:ANRO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alto Neuroscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-10.861/0
= %

Alto Neuroscience's Enterprise Value for the quarter that ended in Dec. 2023 was $0.00 Mil.
Alto Neuroscience's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alto Neuroscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Alto Neuroscience (Alto Neuroscience) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus